Products new and old take Pfizer past $6bn threshold in Japan
This article was originally published in Scrip
Growth for most mainstay products, new launches, the June 2010 local merger with Wyeth and entry into the branded generics sector all combined to propel Pfizer to the top spot in Japan's prescription market last year, at least by some measures.
You may also be interested in...
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.